Toprol-XL patents found invalid
Executive Summary
The U.S. Court of Appeals for the Federal Circuit upheld a district court ruling that AstraZeneca's Toprol-XL (metoprolol succinate) patents are invalid and unenforceable based on double patenting. However, the court vacated the lower court's finding of inequitable conduct by AstraZeneca. The court concluded that there are questions of fact involving AstraZeneca's failure to disclose a dispute over inventorship to the U.S. Patent and Trademark Office and sent the issue back to the U.S. District Court for the Eastern District of Missouri for review. AstraZeneca filed suit against KV Pharmaceutical, Andrx and Eon Labs after they filed ANDAs to market generic versions of the hypertension treatment. Sandoz and KV subsequently filed citizen petitions to block each other from marketing formulations of the drug (1"The Pink Sheet" July 9, 2007, p. 26)...
You may also be interested in...
Generic Firms Use Pediatric Exclusivity As Weapon In Toprol XL Fight
Sandoz and KV Pharmaceutical are locked in a regulatory struggle to keep each other's generic versions of AstraZeneca's Toprol XL (metoprolol extended release) off the market
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.